TrinityPoint Wealth’s Kyntra Bio KYNB Stock Holding History

TrinityPoint Wealth’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-448	Closed	-$134K	–	287
2022 Q1	$134K	Buy	+448	New	+$156K	0.02%	304

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

TrinityPoint Wealth's KYNB Position: Q2 2022 in Review

TrinityPoint Wealth sold out of Kyntra Bio (KYNB) in Q2 2022, closing a stake of 448 shares — an estimated $134K sold.

TrinityPoint Wealth first reported a position in KYNB in Q1 2022 and held it in 1 quarter. The position peaked at $134K in Q1 2022. 150 funds tracked by Wall St. Rank hold KYNB as of Q2 2022.

TrinityPoint Wealth reported no remaining Kyntra Bio position as of Q2 2022 after selling out during the quarter.
TrinityPoint Wealth sold 448 Kyntra Bio shares in Q2 2022, an estimated $134K.
TrinityPoint Wealth first reported a position in Kyntra Bio in Q1 2022 and held it in 1 quarter.
TrinityPoint Wealth's Kyntra Bio position peaked at $134K in Q1 2022.
150 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2022.

Based on TrinityPoint Wealth's 13F filing for Q2 2022, filed 5 Aug 2022.